We believe the MHRA should be independently reviewed. This should cover approval and surveillance processes, funding & accountability. It should consider how to ensure the transparency of decisions, prioritisation of patient safety, and how to ensure there aren’t conflict of interests.

A wide range of medicines & devices approved by MHRA have caused patient harm & it often takes too long for action to be taken. We think an urgent review of the yellowcard system is required. We consider that the MHRA focuses too much on clinical trials of new medicines, rather than safety of existing ones. There is a 'revolving door' between industry & the regulator, several board members declare interests. Some information sought through FOIs has not been provided due to commercial interests.